annual meeting program - American Society of Clinical Oncology

FRIDAY
Friday, June 4, 2010
Brd. 21 A phase II study of sorafenib in combination with carboplatin and paclitaxel
in patients with metastatic or recurrent squamous cell cancer of the head and
neck (SCCHN). (Abstract #5532)
A. L. Sabichi, M. S. Kies, B. S. Glisson, C. Lu, L. E. Ginsberg, C. I. Bartos, L. Feng,
H. T. Tran, S. M. Lippman, G. R. Blumenschein Jr.
Brd. 22 Pemetrexed (P) and bevacizumab (B) in patients (pts) with recurrent or
metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN):
Final results and correlation with TS, MTHFR, and VEGF gene
polymorphisms. (Abstract #5533)
A. Argiris, M. Karamouzis, W. E. Gooding, B. Branstetter, S. Zhong, L. E. Raez,
P. Savvides, M. Romkes
Brd. 23 Is there a role for adjuvant cetuximab after radiotherapy (RT) plus cetuximab
in patients (pts) with locally advanced squamous cell carcinoma of the
oropharynx? A phase II randomized trial. (Abstract #5534)
R. Mesia, A. Rueda, R. Vera, A. Lozano, J. A. Medina, D. Aguiar Bujanda III, F.
Arias de la Vega, G. Triana, M. Guix, R. Lopez
Brd. 24 Chemoprevention with erlotinib and celecoxib in advanced premalignant
lesions of the head and neck: Results of a phase I study. (Abstract #5535)
N. F. Saba, S. Muller, A. Y. Chen, W. Grist, K. Gibson, S. Nannapaneni,
C. S. Yang, F. R. Khuri, Z. G. Chen, D. M. Shin
Brd. 25 Phase II study and tissue correlative studies of AZD6244 (ARRY-142886) in
iodine-131 refractory papillary thyroid carcinoma (IRPTC) and papillary
thyroid carcinoma (PTC) with follicular elements. (Abstract #5536)
A. S. Lucas, E. E. Cohen, R. B. Cohen, M. K. Krzyzanowska, C. H. Chung,
B. A. Murphy, T. Tanvetyanon, J. Gilbert, D. T. Moore, D. N. Hayes
68